Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37254370)
Watch
English
Vascular targeted therapies in oncology
scientific article published on 28 August 2008
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Vascular targeted therapies in oncology
(English)
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
author name string
Dietmar W Siemann
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
Michael R Horsman
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
publication date
28 August 2008
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
published in
Cell and Tissue Research
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
volume
335
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
issue
1
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
page(s)
241-248
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
exact match
https://scigraph.springernature.com/pub.10.1007/s00441-008-0646-0
0 references
cites work
An update on the clinical development of drugs to disable tumor vasculature
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Current development status of small-molecule vascular disrupting agents
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Disrupting tumour blood vessels
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Differentiation and definition of vascular-targeted therapies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Therapeutic strategies that selectively target and disrupt established tumor vasculature
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Vascular-targeting therapies for treatment of malignant disease.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Vascular targeting agents as cancer therapeutics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Specialization of tumour vasculature
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Role of angiogenesis in tumor growth and metastasis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Overview of angiogenesis: Biologic implications for antiangiogenic therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Tumor angiogenesis: past, present and the near future
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
New strategies in anti-vascular cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Tumour vasculature as a target for cancer therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
6 September 2017
Microvascular corrosion casting in the study of tumor vascularity: a review.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
28 September 2017
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
26 June 2018
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
26 June 2018
Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
26 June 2018
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
DMXAA: an antivascular agent with multiple host responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2788502
retrieved
3 September 2018
Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18752004
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/18752004
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1007/S00441-008-0646-0
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
PMCID
2788502
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
PubMed ID
18752004
1 reference
stated in
Europe PubMed Central
PMCID
2788502
retrieved
19 August 2017
ResearchGate publication ID
23218649
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
